Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
← catalyst calendarNCT04501120 · readout ≤ 773 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Suzhou Yasheng Pharmaceutical Co., Ltd..
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
682estimated
Sites
12
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-28 | actual | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy
Interventions
- Drug: Lisaftoclax (APG-2575)
- Drug: Reduced-dose HHT
- Drug: standard-dose HHT
- Drug: Azacitidine
- Drug: Lisaftoclax (APG-2575)
- Drug: olverembatinib
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicities (DLT)
measured 28 days
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)
measured 28 days
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed